A Study evaluating the magnitude and distribution of neuro-inflammation using [11C]PK11195 PET in patients with Lewy body Dementia as compared to Healthy controls

Trial Profile

A Study evaluating the magnitude and distribution of neuro-inflammation using [11C]PK11195 PET in patients with Lewy body Dementia as compared to Healthy controls

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Aug 2017

At a glance

  • Drugs Carbon-11 PK 11195 (Primary)
  • Indications Lewy body disease
  • Focus Diagnostic use
  • Acronyms NIMROD
  • Most Recent Events

    • 28 Aug 2017 New trial record
    • 20 Jul 2017 Results presented at the Alzheimer's Association International Conference 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top